S. Dhuria

发表

Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

W. Frey, L. Hanson, S. Dhuria, 2010, Journal of pharmaceutical sciences.

Ribociclib Drug-Drug Interactions - Clinical Evaluations and PBPK Modeling to Guide Drug Labeling.

T. Heimbach, A. Chakraborty, Hilmar Schiller, 2020, Clinical pharmacology and therapeutics.

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations

C. Germa, K. Umehara, S. Dhuria, 2017, Clinical pharmacology and therapeutics.

Food consumption and activity levels increase in rats following intranasal Hypocretin-1

Deborah Bingham, J. Fine, L. Hanson, 2016, Neuroscience Letters.

Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.

L. Chow, A. Bardia, N. Harbeck, 2015 .

Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors.

J. Infante, R. Cohen, S. Dhuria, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

A. Bardia, F. Meric-Bernstam, F. Penault-Llorca, 2016, Breast.

Intranasal Targeting of Neuropeptides to the Central Nervous System: Evaluation of Pharmacokinetics, Pharmacodynamics, and a Novel Vasoconstrictor Formulation

S. Dhuria, 2009 .

Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System

L. Hanson, S. Dhuria, William H Frey II, 2009, Journal of Pharmacology and Experimental Therapeutics.

No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects

Aryun Kim, S. Dhuria, T. Choi, 2019, Clinical pharmacology in drug development.

LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2

K. Blackwell, J. Kim, S. Verma, 2016 .

Abstract 2775: A phase I study of LCL161, an oral IAP inhibitor, in patients with advanced cancer

D. Porter, L. Zawel, H. Burris, 2010 .

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

L. Hanson, S. Dhuria, William H Frey II, 2009, Journal of pharmaceutical sciences.

Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics

G. Hortobagyi, F. André, M. Campone, 2016 .

Time‐Dependent Inhibition and Induction of Human Cytochrome P4503A4/5 by an Oral IAP Antagonist, LCL161, In Vitro and In Vivo in Healthy Subjects

Suman Sen, S. Dhuria, J. Mangold, 2013, Journal of clinical pharmacology.

A phase I food-effect study of the ribociclib (LEE011) drug-in-capsule (DiC) formulation in healthy subjects.

C. Germa, S. Dhuria, Ravi K. Siddani, 2015 .

DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1/2 study

A. Bakardjiev, M. Troyer, Akhil Bhalla, 2023, Molecular Genetics and Metabolism.

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2–) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

D. Juric, M. Campone, P. Munster, 2016 .